INNATE PHARMA
🏢 View company profile →93Patents
88Active
93Granted
53Portfolio score
Filing activity: Dec 27, 2001 → Jun 30, 2022 · 16 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8119775B2 | Human anti-KIR antibodies | Chemistry; Metallurgy | 38 | Active |
| US9764038B2 | Enzymatic conjugation of antibodies | Chemistry; Metallurgy | 23 | Active |
| US9447185B2 | Compositions and methods for treating proliferative disorders | Human Necessities | 21 | Active |
| US9067997B2 | Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders | Emerging Cross-Sectional Technologies | 20 | Active |
| US9427478B2 | Enzymatic conjugation of polypeptides | Chemistry; Metallurgy | 17 | Active |
| US8993319B2 | Monoclonal antibodies against NKG2A | Physics | 16 | Active |
| US7803376B2 | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds | Physics | 16 | Active |
| US10329348B2 | Treatment of cancers using anti-NKG2A agents | Chemistry; Metallurgy | 15 | Active |
| US10059765B2 | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds | Physics | 15 | Active |
| US10160810B2 | Monoclonal antibodies against NKG2A | Physics | 14 | Active |
| US8981065B2 | Human anti-KIR antibodies | Chemistry; Metallurgy | 13 | Active |
| US9717803B2 | Enzymatic conjugation of polypeptides | Chemistry; Metallurgy | 12 | Active |
| US9090876B2 | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds | Physics | 12 | Active |
| US7732131B2 | Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor | Chemistry; Metallurgy | 10 | Active |
| US10113003B2 | Multispecific NK engager proteins | Chemistry; Metallurgy | 9 | Active |
| US8637258B2 | Compositions and methods for regulating NK cell activity | Chemistry; Metallurgy | 9 | Active |
| US9828427B2 | Anti-KIR3D antibodies | Chemistry; Metallurgy | 8 | Active |
| US9181341B2 | Anti-KIR3D antibodies | Chemistry; Metallurgy | 8 | Active |
| US8017596B2 | Phosphonates useful as modulators of T-γ-9-δ-2 activity | Chemistry; Metallurgy | 8 | Active |
| US6979546B2 | Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same | Emerging Cross-Sectional Technologies | 8 | Expired |
| US10174112B2 | Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma | Physics | 8 | Active |
| US10711063B2 | Neutralization of inhibitory pathways in lymphocytes | Chemistry; Metallurgy | 7 | Active |
| US10280222B2 | Humanized antibodies with increased stability | Chemistry; Metallurgy | 7 | Active |
| US9902936B2 | PAN-KIR2DL NK-receptor antibodies and their use in diagnostics and therapy | Emerging Cross-Sectional Technologies | 7 | Active |
| US10434180B2 | Enzymatic conjugation of polypeptides | Chemistry; Metallurgy | 7 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.